Antimicrobial activity and beta-lactamase stability of BMY-28232, parent compound of an oral cephalosporin.
BMY-28232, an aminothiazolyl imino methoxy cephalosporin which is available as an orally absorbed acetoxyethyl ester, inhibited strains of methicillin-susceptible Staphylococcus aureus, hemolytic streptococci, Streptococcus pneumoniae, Escherichia coli, Klebsiella species, and many strains of Proteus and Providencia stuartii at concentrations less than 1 microgram/ml, including isolates resistant to cephalexin and cefaclor. It had activity similar to that of cefixime, but was more active against methicillin-susceptible staphylococci. BMY-28232 was a poor substrate for beta-lactamases but was destroyed by the new TEM-3 enzyme, and had less activity against Enterobacter species, Citrobacter freundii, and Proteus vulgaris isolates. Methicillin-resistant staphylococci, Pseudomonas species, enterococci, Listeria monocytogenes, Corynebacterium jeikeium, Bacteroides fragilus and some strains of Clostridium species were resistant to BMY-28232.
Chin
N X
NX
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032.
Yu
K W
KW
Neu
H C
HC
D001419:Bacteria / Q000187:drug effects*; D002511:Cephalosporins / Q000378:metabolism / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D006868:Hydrolysis; D007709:Klebsiella / Q000187:drug effects; D016106:Methicillin Resistance; D011511:Proteus / Q000187:drug effects; D011532:Providencia / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D001618:beta-Lactamases / Q000378:metabolism*
D002511:Cephalosporins; C058032:BMY 28232; D001618:beta-Lactamases